Harpoon Therapeutics Inc (HARP) has released an update.
Harpoon Therapeutics is on course to become a wholly-owned subsidiary of Merck, following a merger agreement reached earlier this year. With the critical Hart-Scott-Rodino antitrust waiting period having expired, the deal’s finalization now hinges on other customary conditions, including approval by Harpoon’s stockholders at an upcoming special meeting. Investors are encouraged to peruse the detailed proxy statement and other relevant materials filed with the SEC to understand the implications of the merger, available through various investor relations channels.
For further insights into HARP stock, check out TipRanks’ Stock Analysis page.
